On 8 March 2004, orphan designation (EU/3/04/189) was granted by the European Commission to Promedipharm GmbH, Germany, for idebenone for the treatment of Friedreich's ataxia.
The sponsorship was transferred to Santhera Pharmaceuticals (Deutschland) AG in December 2005.
The name of the sponsor changed to Santhera Pharmaceuticals (Deutschland) GmbH in September 2010.
Treatment of Friedreich's ataxia
|Orphan designation status||
|EU designation number||
|Date of designation||
Santhera Pharmaceuticals (Deutschland) GmbH
Documents related to this orphan designation evaluation
For contact details of patients’ organisations whose activities are targeted at rare diseases, see:
European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.
Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.
EU register of orphan medicines
The list of medicines that have received an orphan designation in the EU is available on the European Commission's website: